Abstract
Evidence from clinical trials suggest anti-SARS-CoV-2 monoclonal antibodies (mABs) may reduce coronavirus disease 2019 (COVID-19)-related hospitalizations. The purpose of this study was to assess the real-world impact of mAB administration on COVID-19 hospitalization among patients 65 years or older. This was a retrospective, propensity-matched cohort study that included patients aged 65 years and older who presented to the emergency department (ED) within 10 days of symptom onset of mild to moderate COVID-19 infection. Outcomes were compared between those who did and did not receive mAB therapy. The primary endpoint was the rate of hospitalization for COVID-19 within 30 days of index ED visit. A total of 137 patients receiving mABs were matched to 137 controls. Hospitalization occurred in 2.9% of mAB-treated patients compared to 14.6% of patients of the standard of care (SOC) arm (odds ratio: 0.20 [95% CI: 0.07-0.59]). There were zero intubations and zero deaths compared to 3 (2.2%) and 2 (1.5%) in the SOC group. Among the 223 patients receiving mAB in the overall cohort, adverse drug events occurred in 10 (4.5%). Treatment with mAB therapy for mild to moderate COVID-19 was associated with a substantially reduced risk of hospitalization among patients at least 65 years of age.
Keywords: COVID-19; anti-SARS-CoV-2 monoclonal antibodies; bamlanivimab; casirivimab + imdevimab; older adults.
【저자키워드】 COVID-19, Older adults, anti-SARS-CoV-2 monoclonal antibodies, bamlanivimab, casirivimab + imdevimab, 【초록키워드】 coronavirus disease, clinical trial, therapy, Hospitalization, monoclonal antibody, Infection, intubation, anti-SARS-CoV-2, Moderate COVID-19, cohort study, Adults, Cohort, hospitalizations, Patient, death, Mild, COVID-19 hospitalization, age, monoclonal, retrospective, administration, primary endpoint, Standard of care, symptom onset, Older, reduced risk, controls, event, occurred, receiving, reduce, receive, 【제목키워드】 monoclonal antibody, anti-SARS-CoV-2, COVID-19 hospitalization, regimen, Older,